Americhem acquires Noble Biomaterials, adds US production capacity

Americhem has acquired Noble Biomaterials, bringing a Pennsylvania-based developer of antimicrobial and conductive finishes into the Ohio polymer group’s US production footprint. Noble founder and chief commercial officer Joel Furey said: “Americhem is the right partner for Noble Biomaterials’ next chapter, bringing complementary capabilities, global reach, scalable resources, and a customer-first culture that will drive lasting value.”

Furey said the acquisition would extend Noble’s proprietary Ionic+, X-Static and Circuitex brands through Americhem’s global scale and deep knowledge of polymer and fiber applications. He also said he was proud of the team and excited about what the two companies would accomplish together.

Noble develops proprietary materials for apparel and textiles, healthcare, aerospace and defense. The acquisition joins Noble’s antimicrobial and conductive technologies with Americhem’s established polymer business.

What does Noble add to Americhem’s portfolio?

Noble’s portfolio includes FDA-registered medical devices and EPA-registered antimicrobial finishes, according to the company’s description of the acquisition. Its Ionic+ technology uses a silver-based fabric finish to provide antimicrobial benefits for textiles and apparel. Circuitex supplies lightweight, flexible, conductive and reflective materials for military applications.

How does the acquisition change supply capacity?

Americhem, an Ohio-based global polymer manufacturer, specializes in polymers for stain- and water-repellence in textiles. Earlier this year, it introduced nDryve, described by the company as a PFAS-free solution for liquid repellence.

Americhem CEO John Richard said: “This is an exciting step forward for Americhem as we continue to invest in high-growth, high-demand markets.” He said Noble brings antimicrobial solutions, strong commercial relationships and a quality reputation that align with Americhem’s values.

He added that the combination should position Americhem to deliver specialized solutions for customers worldwide as it invests in healthcare and aerospace and defense. nDryve allows fibers to repel liquids, including alcohol, without a separate surface treatment. The repellent function is added during melt processing, and Americhem targets medical materials, apparel and carpets with the coating.

Americhem’s acquisition adds US production capability to its polymer and specialty-materials portfolio. The announcement confirms the ownership change but does not disclose customer orders, production targets, financial terms or a timeline for expanding Noble’s output.

It sets out no customer volume commitments for the combined business. That leaves the confirmed deal separate from any assumption about immediate order shifts or market rumors.

Pritzker Private Capital supported the acquisition. Principal Kaitlyn Desai said Noble’s technology and market focus align with Americhem’s strategic direction, and she said the deal reinforces PPC’s conviction in Americhem’s growth strategy and capabilities.

She said PPC would continue supporting Americhem’s ambition to become a global leader in specialized polymers and advanced materials solutions. The investor also backs chemical producers including Buckman, which works with the leather industry.

What must buyers verify on the PFAS-free claim?

nDryve’s PFAS-free description is a compliance claim that needs documentary support before buyers use it in a purchasing specification. The announcement identifies no test method, certification standard or applicable law for that description, so procurement teams need substantiation from Americhem.

The announcement cites FDA registration for medical devices and EPA registration for antimicrobial finishes; it makes no separate approval claim for either. Buyers should also request evidence for Ionic+’s silver-based antimicrobial performance and Circuitex’s conductive and reflective performance in military applications.

For sourcing teams, the decision is narrower than Americhem’s stated global ambitions: qualify the acquired US capacity and nDryve for specific programs, then seek order, capacity and compliance documentation. The ownership change is confirmed; the scale of any production expansion, customer commitments and standards behind the PFAS-free claim are not.